IPP Bureau
Indian Health Minister Dr. Mandaviya addresses 76th session of the WHO Regional Committee for South-East Asia
By IPP Bureau - October 31, 2023
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
By IPP Bureau - October 31, 2023
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Alkem ‘Healthy Lungs' initiative aims to clear the air
By IPP Bureau - October 31, 2023
The initiative will focus on advocating for cleaner air
Lubrizol launches carbopol polymers for nutraceuticals with new EU good grade approval
By IPP Bureau - October 31, 2023
The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
By IPP Bureau - October 30, 2023
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
EnginZyme produces key mRNA vaccine ingredient using biocatalysis
By IPP Bureau - October 30, 2023
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Tanaka develops first high entropy precious metals alloy powder
By IPP Bureau - October 30, 2023
With the establishment of five different precious metals alloy powder production methods
Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
By IPP Bureau - October 30, 2023
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
By IPP Bureau - October 30, 2023
The companies plan to start a pivotal Phase 3 trial in the coming months
Mandaviya inaugurates Rural Health Training Centre (RHTC) Hospital in Najafgarh, Delhi
By IPP Bureau - October 26, 2023
RHTC will address a long-standing healthcare access issue for all the local population
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer
By IPP Bureau - October 26, 2023
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
By IPP Bureau - October 26, 2023
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Venus Remedies earns REO Certification from CII for second consecutive year
By IPP Bureau - October 26, 2023
The Responsible Export Organisation (REO) certification is a distinguished recognition awarded by the Confederation of Indian Industry (CII)
Lilly's Retevmo phase 3 results in RET fusion-positive non-small cell lung cancer
By IPP Bureau - October 26, 2023
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
BASF Pharma Solutions introduces premium services to its VPAs digital services platform
By IPP Bureau - October 25, 2023
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
